Status:
COMPLETED
FIbrosis and Steatosis in Patients With Psychiatric Illness
Lead Sponsor:
Centre Hospitalier Esquirol
Conditions:
Severe Bipolar I Disorder (Diagnosis)
Bipolar I Disorder, Most Recent Episode Mixed, in Remission
Eligibility:
All Genders
18+ years
Brief Summary
Background: Severe psychiatric diseases (schizophrenia, bipolarity, depression, anxious syndrome) are often associated with a metabolic syndrome, including Non-Alcoholic Steato Hepatitis, probably mis...
Detailed Description
Patients with psychiatric illness are often exposed to an increase risk of mortality compared to the general population: a reduction of life expectancy between 7 and 24 years has been described . Soma...
Eligibility Criteria
Inclusion
- Patients with a severe psychiatric disorder (psychotic disorder, mood disorder, anxiety or anxiety disorder), and under psychotropic treatment (neuroleptic and/or antidepressant) for at least two years.
- and/or antidepressant) for at least two years, and hospitalized in units treating these disorders in the investigating centers.
- \- Subjects or their legal representatives who have given informed consent, with social insurance, aged over 18 years of age.
Exclusion
- Short-term life-threatening conditions
- Liver disease already diagnosed at inclusion: cancer, cirrhosis, chronic or acute or acute liver disease
- No antipsychotic or antidepressant treatment
- Anti-viral treatment demonstrating infection with hepatitis viruses or the HIV virus (or known positive HIV serology)
Key Trial Info
Start Date :
October 26 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 12 2021
Estimated Enrollment :
385 Patients enrolled
Trial Details
Trial ID
NCT05965232
Start Date
October 26 2017
End Date
July 12 2021
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Esquirol
Limoges, France, 87025